[go: up one dir, main page]

PE20081354A1 - Compuestos de azaindolilo como inhibidores de mek - Google Patents

Compuestos de azaindolilo como inhibidores de mek

Info

Publication number
PE20081354A1
PE20081354A1 PE2007001679A PE2007001679A PE20081354A1 PE 20081354 A1 PE20081354 A1 PE 20081354A1 PE 2007001679 A PE2007001679 A PE 2007001679A PE 2007001679 A PE2007001679 A PE 2007001679A PE 20081354 A1 PE20081354 A1 PE 20081354A1
Authority
PE
Peru
Prior art keywords
alkyl
fluoro
pyridine
phenylamine
carboxyl
Prior art date
Application number
PE2007001679A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20081354A1 publication Critical patent/PE20081354A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE AZAINDOLILO DE FORMULA (I), DONDE Z1 ES CR1 O N; Z2 ES CR2 O N; Z3 ES CR3 O N; Z4 ES CR4 O N; R1, R2, R3 Y R4 SON H, HALO, CN, CF3, NO2, ENTRE OTROS; W ES X1-NR5- O R11-O-; R5 Y R6 SON H O ALQUILO C1-C12; X1 ES R11, OR11, NR11R12, ENTRE OTROS; X2 ES ARILO, HETEROARILO, ENTRE OTROS; X3 ES H, (CR23R24)pR12, (CR23R24)qNR11R12, ENTRE OTROS; R11 Y R12 SON H, ALQUILO C1-C12, ALQUENILO C2-C8, ARILO, ENTRE OTROS; p ES 1, 2 O 3; q ES 2 O 3; R23 Y R24 SON H O ALQUILO OPCIONALMENTE SUSTITUIDO CON HALO, CIANO, NO2, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO 3-(4-BROMO-2-FLUORO-FENILAMINO)-1-METIL-1H-PIRROLO[3,2-c]PIRIDINA-2-CARBOXILICO, ESTER ETILICO DEL ACIDO 3-(2-FLUORO-4-YODO-FENILAMINO)-1-METIL-1H-PIRROLO[3,2-c]PIRIDINA-2-CARBOXILICO, ESTER ETILICO DEL ACIDO 1-ETIL-3-(2-FLUORO-4-YODO-FENILAMINO)-1H-PIRROLO[3,2-c]PIRIDINA-2-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE LA QUINASA MEK Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS Y/O INFLAMATORIAS
PE2007001679A 2006-11-30 2007-11-29 Compuestos de azaindolilo como inhibidores de mek PE20081354A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
PE20081354A1 true PE20081354A1 (es) 2008-11-14

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001679A PE20081354A1 (es) 2006-11-30 2007-11-29 Compuestos de azaindolilo como inhibidores de mek

Country Status (14)

Country Link
US (1) US7855216B2 (es)
EP (1) EP2099796B1 (es)
JP (1) JP5211063B2 (es)
AR (1) AR064031A1 (es)
AT (1) ATE511509T1 (es)
AU (1) AU2007325123B2 (es)
CA (1) CA2672327A1 (es)
CL (1) CL2007003444A1 (es)
DK (1) DK2099796T3 (es)
PE (1) PE20081354A1 (es)
PL (1) PL2099796T3 (es)
PT (1) PT2099796E (es)
TW (1) TW200829586A (es)
WO (1) WO2008067481A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297070A2 (en) * 2008-07-03 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Mek阻害剤に対する耐性を付与するmek突然変異
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
SG10201505951VA (en) * 2010-07-30 2015-08-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
CN111065393B (zh) 2017-05-19 2023-08-18 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
CA3063535A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CA3120352A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CN113473978B (zh) 2018-11-20 2025-03-28 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン-アニリン化合物
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN118591373A (zh) 2021-11-23 2024-09-03 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的制剂
CA3247162A1 (en) * 2022-01-28 2023-08-03 Insilico Medicine Ip Limited Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
US20250171451A1 (en) * 2022-03-04 2025-05-29 Samjin Pharmaceutical Co., Ltd. Novel heterocyclic compound and pharmaceutical composition comprising same
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20250067072A (ko) * 2023-11-07 2025-05-14 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2483162C (en) * 2002-04-23 2011-08-23 Aventis Pharmaceuticals Inc. Use of 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino benzo[b]thiophene-2-carboxylic acid derivatives as il-4 inhibitors
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
JP5211063B2 (ja) 2013-06-12
ATE511509T1 (de) 2011-06-15
AU2007325123B2 (en) 2012-12-13
EP2099796A1 (en) 2009-09-16
WO2008067481A1 (en) 2008-06-05
PT2099796E (pt) 2011-09-06
AR064031A1 (es) 2009-03-04
CL2007003444A1 (es) 2008-06-27
TW200829586A (en) 2008-07-16
US7855216B2 (en) 2010-12-21
EP2099796B1 (en) 2011-06-01
PL2099796T3 (pl) 2011-10-31
JP2010511626A (ja) 2010-04-15
US20080242655A1 (en) 2008-10-02
CA2672327A1 (en) 2008-06-05
HK1135099A1 (en) 2010-05-28
AU2007325123A1 (en) 2008-06-05
DK2099796T3 (da) 2011-09-05

Similar Documents

Publication Publication Date Title
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20081359A1 (es) Compuestos de azabenzotiofenil como inhibidores de la quinasa mek
PE20091843A1 (es) Inhibidores de catepsina c
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20080315A1 (es) DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20140918A1 (es) Compuestos de benzoxepina inhibidores de la pi3k
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20090903A1 (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
NO20076317L (no) Sammensetning av en tienopyridinblodplateaggregeringsinhibitor
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed